Cargando…

2429. Whole-genome Sequencing of Healthcare-Onset C. difficile Infection (HO-CDI) Cases Shows Widespread Presence of Antimicrobial Resistance Genes

BACKGROUND: Clostridioides difficile infection (CDI) is the most common pathogen to cause healthcare-associated infections. Unlike some other bacterial pathogens antimicrobial treatment is seldom based on culture with susceptibility testing with infrequent surveillance for antimicrobial resistance....

Descripción completa

Detalles Bibliográficos
Autores principales:	Hyun Shin, Jae, Viana da Silva Costa, Deiziane, Parikh, Hardik, Barry, Katie E, Mathers, Amy J, Warren, Cirle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809836/ http://dx.doi.org/10.1093/ofid/ofz360.2107

Ejemplares similares

1211. Response to Fecal Microbiota Transplant (FMT) in Refractory Clostridioides difficile Infection (CDI) is Modest Compared to Recurrent CDI in Hospitalized Patients
por: Shin, Jae Hyun, et al.
Publicado: (2020)

754. A Two-step Testing Algorithm for Hospital-onset Clostridioides difficile Infection (CDI) Reduces Prescribing of C. difficile (CD) Therapy but Its Ability to Guide Treatment Decisions Remains Unclear
por: Dolan, Mackenzie, et al.
Publicado: (2021)

478. Improving Acid Suppression Therapy to Reduce Hospital-Onset C. difficile infection (HO-CDI): Impact of a Novel Analytic Application
por: Eppes, Stephen, et al.
Publicado: (2018)

704. Antibiotic Use Audit in Hospital-onset Clostridioides difficile (HO-CDI) Cases in a Tertiary Medical Center in New York City
por: Swaminathan, Neeraja, et al.
Publicado: (2023)

709. Post-Clostridioides difficile Infection Neuroinflammatory Response in an Animal Model
por: Yang, Suemin E, et al.
Publicado: (2023)

759. Impact of Clostridium difficile (CD) Nucleic Acid Amplification Test (NAAT) Approval on Hospital-Onset C. difficile Infection (HO-CDI): A Diagnostic Stewardship Intervention
por: Touzard-Romo, Francine, et al.
Publicado: (2021)

398. Post-Infectious Irritable Bowel Syndrome in Patients Referred to a Complicated Clostridioides difficile Clinic
por: Pham, Natalie, et al.
Publicado: (2022)

Substantial reduction of healthcare facility-onset Clostridioides difficile infection (HO-CDI) rates after conversion of a hospital for exclusive treatment of COVID-19 patients
por: Ochoa-Hein, Eric, et al.
Publicado: (2021)

Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes
por: Madden, Gregory R., et al.
Publicado: (2022)

2429. The Epidemiology and Outcomes of Enterobacter cloacae Bloodstream Infections in Children
por: Alhajri, Noora, et al.
Publicado: (2018)

Collection of 2429 constrained headshots of 277 volunteers for deep learning
por: Aoto, Saki, et al.
Publicado: (2022)

Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI
por: Finn, Elaine, et al.
Publicado: (2021)

974. Impact of Mandatory Infectious Disease (ID) Specialist Approval on Hospital-Onset Clostridium difficile (HO-CDI) Testing and Infection Rates: Results of a Pilot Study
por: Lin, Michael Y, et al.
Publicado: (2018)

New advances in the treatment of Clostridium difficile infection (CDI)
por: Hedge, Dennis D, et al.
Publicado: (2008)

Eight Years of Antimicrobial Stewardship Program (ASP) at a Large Academic Medical Center: Antibiotic Utilization, Hospital-onset Clostridium difficile infection (HO-CDI) and Resistance Trends
por: Dubrovskaya, Yanina, et al.
Publicado: (2017)

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI
por: Sattar, Abdul, et al.
Publicado: (2015)

684. Characteristics of Patients with Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences
por: Guh, Alice, et al.
Publicado: (2023)

Factors associated with an outbreak of hospital-onset, healthcare facility-associated Clostridium difficile infection (HO-HCFA CDI) in a Mexican tertiary care hospital: A case-control study
por: Ochoa-Hein, Eric, et al.
Publicado: (2018)

Clostridioides difficile infection (CDI) during the COVID-19 pandemic
por: Spigaglia, Patrizia
Publicado: (2022)

Use of Electronic Data to Identify Risk Factors Associated with Clostridium difficile Infection (CDI) and to Develop CDI Risk Scores
por: Aukes, Laurie, et al.
Publicado: (2017)

1930. Quality of Life among Patients with Community-onset Clostridioides difficile Infection (CDI) without Subsequent Hospitalization
por: Schmidt, Mark A, et al.
Publicado: (2023)

2429. Epidemiology and Risk Factors for Vascular Access-associated Infections in Japanese Hemodialysis Patients
por: Morikane, Keita
Publicado: (2023)

A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018
por: Viprey, Virginie F, et al.
Publicado: (2022)

Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
por: Golan, Yoav, et al.
Publicado: (2017)

Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)
por: Kullar, Ravina, et al.
Publicado: (2020)

2365. Volatile Metabolite-Based Detection of Clostridium difficile Infection (CDI)
por: Aloum, Obadah, et al.
Publicado: (2019)

2353. Easy Does It: Decreasing and Sustained Hospital-Onset (HO) CDI Lab-ID Event Incidence Through a Series of Interventions
por: Lee, Rachael A, et al.
Publicado: (2019)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

COVID-19 and Clostridioides difficile infection (CDI): Possible implications for elderly patients
por: Spigaglia, Patrizia
Publicado: (2020)

Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2014)

Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS)
por: Dorr, Mary Beth, et al.
Publicado: (2017)

Adenosine receptors differentially mediate enteric glial cell death induced by Clostridioides difficile Toxins A and B
por: Costa, Deiziane V. S., et al.
Publicado: (2023)

135. Impact of Clostridioides difficile Toxin Confirmation on Subsequent C. difficile Treatment in a Rural Health System (IT-CDI)
por: Crawford, Jacquelyn, et al.
Publicado: (2023)

The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases
por: Olsen, Margaret A., et al.
Publicado: (2016)

527 Age-Related Changes in the Incidence of Community-Associated Clostridium Difficile Infection (CDI)
por: Faden, Howard
Publicado: (2014)

485. On- and Post-Antibiotic Effects on the Risk of Hospital-Acquired Clostridium difficile Infection (CDI)
por: Stevens, Vanessa, et al.
Publicado: (2018)

Incidence of Clostridioides difficile infection (CDI) related to antibiotic prescribing by GP surgeries in Wales
por: Tydeman, Florence, et al.
Publicado: (2021)

Clostridioides difficile infection (CDI) treatment outcomes and recurrence factor at a pediatric hospital
por: Tran, Martin Tuan, et al.
Publicado: (2022)

Biofilm Formation of Clostridioides difficile, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI
por: Dicks, Leon M. T.
Publicado: (2023)

Genotypic Correlation between Cases of Clostridium difficile (CDI) with Community-Onset Diagnosis after Recent Hospital Discharge and Their Prior Unit-Based Contacts
por: Aslam, Anoshé, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4i9isg6jeovdbnrl5n7o3c65to